101 related articles for article (PubMed ID: 8408728)
1. The disposition of doxorubicin on repeated dosing.
Rushing DA; Piscitelli SC; Rodvold KA; Tewksbury DA
J Clin Pharmacol; 1993 Aug; 33(8):698-702. PubMed ID: 8408728
[TBL] [Abstract][Full Text] [Related]
2. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
Conley BA; Egorin MJ; Whitacre MY; Carter DC; Zuhowski EG; Van Echo DA
Cancer Chemother Pharmacol; 1993; 33(2):107-12. PubMed ID: 8261569
[TBL] [Abstract][Full Text] [Related]
8. Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients.
Morris RG; Reece PA; Dale BM; Green RM; Kotasek D; Saccoia NC; Sage RE
Ther Drug Monit; 1989; 11(4):380-3. PubMed ID: 2741185
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
12. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
14. Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.
Erlichman C; Soldin SJ; Hardy RW; Thiessen JJ; Sturgeon JF; Fine S; Baskerville T
Arzneimittelforschung; 1988 Jun; 38(6):839-42. PubMed ID: 3178926
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin clearance in the obese.
Rodvold KA; Rushing DA; Tewksbury DA
J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
Holmes FA; Madden T; Newman RA; Valero V; Theriault RL; Fraschini G; Walters RS; Booser DJ; Buzdar AU; Willey J; Hortobagyi GN
J Clin Oncol; 1996 Oct; 14(10):2713-21. PubMed ID: 8874332
[TBL] [Abstract][Full Text] [Related]
20. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
